These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36999519)

  • 1. Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism.
    Park H; Jones BL; Huang PL; Kang HR; Dietrich EA; DeRemer CE; Lo-Ciganic WH
    Ann Pharmacother; 2023 Dec; 57(12):1349-1360. PubMed ID: 36999519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trajectories of adherence to extended treatment with direct oral anticoagulants and risks of recurrent venous thromboembolism and major bleeding.
    Kang HR; Jones BL; Lo-Ciganic WH; DeRemer CE; Dietrich EA; Huang PL; Wilson DL; Park H
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1219-1230. PubMed ID: 37889866
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism.
    Park H; Kang HR; Huang PL; Lo-Ciganic WH; DeRemer CE; Wilson D; Dietrich EA
    Clin Transl Sci; 2023 Jan; 16(1):128-139. PubMed ID: 36200137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding.
    Kang HR; Jones BL; Lo-Ciganic WH; DeRemer CE; Dietrich EA; Huang PL; Park H
    Res Pract Thromb Haemost; 2023 Mar; 7(3):100131. PubMed ID: 37159747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Safety of Extended Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: A Retrospective Cohort Study.
    Kang HR; Lo-Ciganic WH; DeRemer CE; Dietrich EA; Huang PL; Park H
    Clin Pharmacol Ther; 2022 Jul; 112(1):133-145. PubMed ID: 35420702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
    Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
    Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism.
    Fang MC; Reynolds K; Fan D; Prasad PA; Sung SH; Portugal C; Garcia E; Go AS
    JAMA Netw Open; 2023 Aug; 6(8):e2328033. PubMed ID: 37581888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
    J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism.
    Kang HR; Dietrich EA; Huang PL; Lo-Ciganic WH; DeRemer CE; Park H
    Clin Transl Sci; 2023 Jun; 16(6):946-954. PubMed ID: 36891985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
    Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
    Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
    [No Abstract]   [Full Text] [Related]  

  • 15. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.
    Chen SY; Wu N; Gulseth M; LaMori J; Bookhart BK; Boulanger L; Fields L; Schein J
    J Manag Care Pharm; 2013 May; 19(4):291-301. PubMed ID: 23627575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Direct Oral Anticoagulants vs. Warfarin and Recurrence After Discontinuation in Patients With Acute Venous Thromboembolism in the Real World.
    Hara N; Lee T; Nozato T; Terui Matsuyama M; Okata S; Nagase M; Mitsui K; Nitta G; Watanabe K; Miyazaki R; Nagamine S; Kaneko M; Nakamura T; Nagata Y; Miyamoto T; Obayashi T; Ashikaga T
    Circ J; 2022 May; 86(6):923-933. PubMed ID: 34645732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
    Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status.
    Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Keshishian A; Yuce H; Luo X
    Adv Ther; 2021 Nov; 38(11):5519-5533. PubMed ID: 34570310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
    Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
    Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal Changes in Long-Term Outcomes of Venous Thromboembolism From the Warfarin Era to the Direct Oral Anticoagulant Era.
    Kaneda K; Yamashita Y; Morimoto T; Chatani R; Nishimoto Y; Ikeda N; Kobayashi Y; Ikeda S; Kim K; Inoko M; Takase T; Tsuji S; Oi M; Takada T; Otsui K; Sakamoto J; Ogihara Y; Inoue T; Usami S; Chen PM; Togi K; Koitabashi N; Hiramori S; Doi K; Mabuchi H; Tsuyuki Y; Murata K; Takabayashi K; Nakai H; Sueta D; Shioyama W; Dohke T; Nishikawa R; Ono K; Kimura T
    J Am Heart Assoc; 2024 Aug; 13(15):e034412. PubMed ID: 39082425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.